APO Research
Talk to an analyst

APO RESEARCH · REPORT

ERA Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global ERA Drugs Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchERA Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal ERA Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal ERA Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ERA Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal ERA Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global ERA Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for ERA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for ERA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for ERA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the ERA Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the ERA Drugs market include Dr. Reddy's Laboratories, Gilead Sciences, Mylan, Teva, United Therapeutics, Hangzhou Zhongmei Huadong Pharmaceutical, Jiangsu Yunyang Group Pharmaceutical, Qilu Pharmaceutical and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global ERA Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of ERA Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents ERA Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the ERA Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

ERA Drugs Segment by Company

Dr. Reddy's Laboratories

Gilead Sciences

Mylan

Teva

United Therapeutics

Hangzhou Zhongmei Huadong Pharmaceutical

Jiangsu Yunyang Group Pharmaceutical

Qilu Pharmaceutical

Johnson & Johnson

Shanghai Xudong Haipu Pharmaceutical

Shanghai Pharmaceutical Group

Sinotherapeutics

Zhengda Tianqing

ERA Drugs Segment by Type

Ambrisentan

Bosentan

Macitentan

ERA Drugs Segment by Application

Hospital

Clinic

Other

ERA Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global ERA Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions ERA Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify ERA Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze ERA Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ERA Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ERA Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ERA Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the ERA Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ERA Drugs industry.

Chapter 3: Detailed analysis of ERA Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of ERA Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of ERA Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. ERA Drugs Industry Trends Table 2. ERA Drugs Industry Drivers Table 3. ERA Drugs Industry Opportunities and Challenges Table 4. ERA Drugs Industry Restraints Table 5. Global ERA Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global ERA Drugs Revenue Share by Company (2021-2026) Table 7. Global ERA Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global ERA Drugs Sales Volume Share by Company (2021-2026) Table 9. Global ERA Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global ERA Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global ERA Drugs Key Company Manufacturing Base & Headquarters Table 12. Global ERA Drugs Company, Product Type & Application Table 13. Global ERA Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global ERA Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ambrisentan Table 18. Significant Companies of Bosentan Table 19. Significant Companies of Macitentan Table 20. Global ERA Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global ERA Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global ERA Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global ERA Drugs Sales Volume Share by Type (2021-2026) Table 24. Global ERA Drugs Sales Volume Share by Type (2027-2032) Table 25. Global ERA Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global ERA Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global ERA Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global ERA Drugs Sales Value Share by Type (2021-2026) Table 29. Global ERA Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Other Table 33. Global ERA Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global ERA Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global ERA Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global ERA Drugs Sales Volume Share by Application (2021-2026) Table 37. Global ERA Drugs Sales Volume Share by Application (2027-2032) Table 38. Global ERA Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global ERA Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global ERA Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global ERA Drugs Sales Value Share by Application (2021-2026) Table 42. Global ERA Drugs Sales Value Share by Application (2027-2032) Table 43. Global ERA Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global ERA Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global ERA Drugs Sales Market Share by Region (2021-2026) Table 46. Global ERA Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global ERA Drugs Sales Market Share by Region (2027-2032) Table 48. Global ERA Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global ERA Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global ERA Drugs Sales Value Share by Region (2021-2026) Table 51. Global ERA Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global ERA Drugs Sales Value Share by Region (2027-2032) Table 53. Global ERA Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global ERA Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global ERA Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global ERA Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global ERA Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global ERA Drugs Sales Market Share by Country (2021-2026) Table 59. Global ERA Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global ERA Drugs Sales Market Share by Country (2027-2032) Table 61. Global ERA Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global ERA Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global ERA Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global ERA Drugs Sales Value Market Share by Country (2027-2032) Table 65. Dr. Reddy's Laboratories Company Information Table 66. Dr. Reddy's Laboratories Business Overview Table 67. Dr. Reddy's Laboratories ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Dr. Reddy's Laboratories ERA Drugs Product Portfolio Table 69. Dr. Reddy's Laboratories Recent Development Table 70. Gilead Sciences Company Information Table 71. Gilead Sciences Business Overview Table 72. Gilead Sciences ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Gilead Sciences ERA Drugs Product Portfolio Table 74. Gilead Sciences Recent Development Table 75. Mylan Company Information Table 76. Mylan Business Overview Table 77. Mylan ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Mylan ERA Drugs Product Portfolio Table 79. Mylan Recent Development Table 80. Teva Company Information Table 81. Teva Business Overview Table 82. Teva ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Teva ERA Drugs Product Portfolio Table 84. Teva Recent Development Table 85. United Therapeutics Company Information Table 86. United Therapeutics Business Overview Table 87. United Therapeutics ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. United Therapeutics ERA Drugs Product Portfolio Table 89. United Therapeutics Recent Development Table 90. Hangzhou Zhongmei Huadong Pharmaceutical Company Information Table 91. Hangzhou Zhongmei Huadong Pharmaceutical Business Overview Table 92. Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Product Portfolio Table 94. Hangzhou Zhongmei Huadong Pharmaceutical Recent Development Table 95. Jiangsu Yunyang Group Pharmaceutical Company Information Table 96. Jiangsu Yunyang Group Pharmaceutical Business Overview Table 97. Jiangsu Yunyang Group Pharmaceutical ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Jiangsu Yunyang Group Pharmaceutical ERA Drugs Product Portfolio Table 99. Jiangsu Yunyang Group Pharmaceutical Recent Development Table 100. Qilu Pharmaceutical Company Information Table 101. Qilu Pharmaceutical Business Overview Table 102. Qilu Pharmaceutical ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Qilu Pharmaceutical ERA Drugs Product Portfolio Table 104. Qilu Pharmaceutical Recent Development Table 105. Johnson & Johnson Company Information Table 106. Johnson & Johnson Business Overview Table 107. Johnson & Johnson ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Johnson & Johnson ERA Drugs Product Portfolio Table 109. Johnson & Johnson Recent Development Table 110. Shanghai Xudong Haipu Pharmaceutical Company Information Table 111. Shanghai Xudong Haipu Pharmaceutical Business Overview Table 112. Shanghai Xudong Haipu Pharmaceutical ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Shanghai Xudong Haipu Pharmaceutical ERA Drugs Product Portfolio Table 114. Shanghai Xudong Haipu Pharmaceutical Recent Development Table 115. Shanghai Pharmaceutical Group Company Information Table 116. Shanghai Pharmaceutical Group Business Overview Table 117. Shanghai Pharmaceutical Group ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Shanghai Pharmaceutical Group ERA Drugs Product Portfolio Table 119. Shanghai Pharmaceutical Group Recent Development Table 120. Sinotherapeutics Company Information Table 121. Sinotherapeutics Business Overview Table 122. Sinotherapeutics ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Sinotherapeutics ERA Drugs Product Portfolio Table 124. Sinotherapeutics Recent Development Table 125. Zhengda Tianqing Company Information Table 126. Zhengda Tianqing Business Overview Table 127. Zhengda Tianqing ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Zhengda Tianqing ERA Drugs Product Portfolio Table 129. Zhengda Tianqing Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. ERA Drugs Distributors List Table 133. ERA Drugs Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. ERA Drugs Product Image Figure 2. Global ERA Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ERA Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global ERA Drugs Sales (2021-2032) & (K Units) Figure 5. Global ERA Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global ERA Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ambrisentan Image Figure 10. Bosentan Image Figure 11. Macitentan Image Figure 12. Global ERA Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global ERA Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global ERA Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global ERA Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global ERA Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global ERA Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global ERA Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global ERA Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global ERA Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global ERA Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global ERA Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global ERA Drugs Sales Value Share by Application (2021-2032) Figure 27. Global ERA Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global ERA Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global ERA Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global ERA Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America ERA Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America ERA Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe ERA Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe ERA Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific ERA Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific ERA Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America ERA Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America ERA Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa ERA Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa ERA Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt ERA Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt ERA Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt ERA Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. ERA Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. ERA Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Ambrisentan
  • Bosentan
  • Macitentan
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Dr. Reddy's Laboratories
  • Gilead Sciences
  • Mylan
  • Teva
  • United Therapeutics
  • Hangzhou Zhongmei Huadong Pharmaceutical
  • Jiangsu Yunyang Group Pharmaceutical
  • Qilu Pharmaceutical
  • Johnson & Johnson
  • Shanghai Xudong Haipu Pharmaceutical
  • Shanghai Pharmaceutical Group
  • Sinotherapeutics
  • Zhengda Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global ERA Drugs Sales Value (2021-2032)
  4. 1.2.2 Global ERA Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global ERA Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 ERA Drugs Market Dynamics
  1. 2.1 ERA Drugs Industry Trends
  2. 2.2 ERA Drugs Industry Drivers
  3. 2.3 ERA Drugs Industry Opportunities and Challenges
  4. 2.4 ERA Drugs Industry Restraints
3 ERA Drugs Market by Company
  1. 3.1 Global ERA Drugs Company Revenue Ranking in 2025
  2. 3.2 Global ERA Drugs Revenue by Company (2021-2026)
  3. 3.3 Global ERA Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global ERA Drugs Average Price by Company (2021-2026)
  5. 3.5 Global ERA Drugs Company Ranking (2024-2026)
  6. 3.6 Global ERA Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global ERA Drugs Company Product Type and Application
  8. 3.8 Global ERA Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global ERA Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 ERA Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 ERA Drugs Market by Type
  1. 4.1 ERA Drugs Type Introduction
  2. 4.1.1 Ambrisentan
  3. 4.1.2 Bosentan
  4. 4.1.3 Macitentan
  5. 4.2 Global ERA Drugs Sales Volume by Type
  6. 4.2.1 Global ERA Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global ERA Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global ERA Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global ERA Drugs Sales Value by Type
  10. 4.3.1 Global ERA Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global ERA Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global ERA Drugs Sales Value Share by Type (2021-2032)
5 ERA Drugs Market by Application
  1. 5.1 ERA Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global ERA Drugs Sales Volume by Application
  6. 5.2.1 Global ERA Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global ERA Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global ERA Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global ERA Drugs Sales Value by Application
  10. 5.3.1 Global ERA Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global ERA Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global ERA Drugs Sales Value Share by Application (2021-2032)
6 ERA Drugs Regional Sales and Value Analysis
  1. 6.1 Global ERA Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global ERA Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global ERA Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global ERA Drugs Sales by Region (2027-2032)
  5. 6.3 Global ERA Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global ERA Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global ERA Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global ERA Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global ERA Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America ERA Drugs Sales Value (2021-2032)
  12. 6.6.2 North America ERA Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe ERA Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe ERA Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific ERA Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific ERA Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America ERA Drugs Sales Value (2021-2032)
  21. 6.9.2 South America ERA Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa ERA Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa ERA Drugs Sales Value Share by Country, 2025 VS 2032
7 ERA Drugs Country-level Sales and Value Analysis
  1. 7.1 Global ERA Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global ERA Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global ERA Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global ERA Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global ERA Drugs Sales by Country (2027-2032)
  6. 7.4 Global ERA Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global ERA Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global ERA Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA ERA Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA ERA Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA ERA Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada ERA Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada ERA Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada ERA Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico ERA Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico ERA Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico ERA Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany ERA Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany ERA Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany ERA Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France ERA Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France ERA Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France ERA Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. ERA Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. ERA Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. ERA Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy ERA Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy ERA Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy ERA Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain ERA Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain ERA Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain ERA Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia ERA Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia ERA Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia ERA Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands ERA Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands ERA Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands ERA Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries ERA Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries ERA Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries ERA Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China ERA Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China ERA Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China ERA Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan ERA Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan ERA Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan ERA Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea ERA Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea ERA Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea ERA Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India ERA Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India ERA Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India ERA Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia ERA Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia ERA Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia ERA Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia ERA Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia ERA Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia ERA Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil ERA Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil ERA Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil ERA Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina ERA Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina ERA Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina ERA Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile ERA Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile ERA Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile ERA Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia ERA Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia ERA Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia ERA Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru ERA Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru ERA Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru ERA Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia ERA Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia ERA Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia ERA Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel ERA Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel ERA Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel ERA Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE ERA Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE ERA Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE ERA Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey ERA Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey ERA Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey ERA Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran ERA Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran ERA Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran ERA Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt ERA Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt ERA Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt ERA Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Dr. Reddy's Laboratories
  2. 8.1.1 Dr. Reddy's Laboratories Company Information
  3. 8.1.2 Dr. Reddy's Laboratories Business Overview
  4. 8.1.3 Dr. Reddy's Laboratories ERA Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Dr. Reddy's Laboratories ERA Drugs Product Portfolio
  6. 8.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences ERA Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences ERA Drugs Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan ERA Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan ERA Drugs Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Teva
  20. 8.4.1 Teva Company Information
  21. 8.4.2 Teva Business Overview
  22. 8.4.3 Teva ERA Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva ERA Drugs Product Portfolio
  24. 8.4.5 Teva Recent Developments
  25. 8.5 United Therapeutics
  26. 8.5.1 United Therapeutics Company Information
  27. 8.5.2 United Therapeutics Business Overview
  28. 8.5.3 United Therapeutics ERA Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 United Therapeutics ERA Drugs Product Portfolio
  30. 8.5.5 United Therapeutics Recent Developments
  31. 8.6 Hangzhou Zhongmei Huadong Pharmaceutical
  32. 8.6.1 Hangzhou Zhongmei Huadong Pharmaceutical Company Information
  33. 8.6.2 Hangzhou Zhongmei Huadong Pharmaceutical Business Overview
  34. 8.6.3 Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Product Portfolio
  36. 8.6.5 Hangzhou Zhongmei Huadong Pharmaceutical Recent Developments
  37. 8.7 Jiangsu Yunyang Group Pharmaceutical
  38. 8.7.1 Jiangsu Yunyang Group Pharmaceutical Company Information
  39. 8.7.2 Jiangsu Yunyang Group Pharmaceutical Business Overview
  40. 8.7.3 Jiangsu Yunyang Group Pharmaceutical ERA Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Yunyang Group Pharmaceutical ERA Drugs Product Portfolio
  42. 8.7.5 Jiangsu Yunyang Group Pharmaceutical Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical ERA Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical ERA Drugs Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson ERA Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson ERA Drugs Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Shanghai Xudong Haipu Pharmaceutical
  56. 8.10.1 Shanghai Xudong Haipu Pharmaceutical Company Information
  57. 8.10.2 Shanghai Xudong Haipu Pharmaceutical Business Overview
  58. 8.10.3 Shanghai Xudong Haipu Pharmaceutical ERA Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai Xudong Haipu Pharmaceutical ERA Drugs Product Portfolio
  60. 8.10.5 Shanghai Xudong Haipu Pharmaceutical Recent Developments
  61. 8.11 Shanghai Pharmaceutical Group
  62. 8.11.1 Shanghai Pharmaceutical Group Company Information
  63. 8.11.2 Shanghai Pharmaceutical Group Business Overview
  64. 8.11.3 Shanghai Pharmaceutical Group ERA Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shanghai Pharmaceutical Group ERA Drugs Product Portfolio
  66. 8.11.5 Shanghai Pharmaceutical Group Recent Developments
  67. 8.12 Sinotherapeutics
  68. 8.12.1 Sinotherapeutics Company Information
  69. 8.12.2 Sinotherapeutics Business Overview
  70. 8.12.3 Sinotherapeutics ERA Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sinotherapeutics ERA Drugs Product Portfolio
  72. 8.12.5 Sinotherapeutics Recent Developments
  73. 8.13 Zhengda Tianqing
  74. 8.13.1 Zhengda Tianqing Company Information
  75. 8.13.2 Zhengda Tianqing Business Overview
  76. 8.13.3 Zhengda Tianqing ERA Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Zhengda Tianqing ERA Drugs Product Portfolio
  78. 8.13.5 Zhengda Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 ERA Drugs Value Chain Analysis
  2. 9.1.1 ERA Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 ERA Drugs Sales Mode & Process
  6. 9.2 ERA Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 ERA Drugs Distributors
  9. 9.2.3 ERA Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst